The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl +16 more
wiley +1 more source
Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study. [PDF]
Montoro Ferrer A +10 more
europepmc +1 more source
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat +22 more
wiley +1 more source
Dupilumab for Trichothiodystrophy-Case Report and Review of the Literature. [PDF]
O'Mahony J, O'Connor C.
europepmc +1 more source
Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
И. С. Крысанов +3 more
openalex +2 more sources
Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes +6 more
wiley +1 more source
Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek +9 more
wiley +1 more source
Dupilumab efficacy across serum
Claus Bachert +19 more
openalex +1 more source
A Case of Acute Pericarditis and Hypereosinophilia After Dupilumab Initiation. [PDF]
Truong T +4 more
europepmc +1 more source
Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP [PDF]
Audrey Pelletier +5 more
openalex +1 more source

